Show simple item record

dc.contributor.authorTsang, RSM
dc.contributor.authorJoy, M
dc.contributor.authorByford, R
dc.contributor.authorRobertson, C
dc.contributor.authorAnand, SN
dc.contributor.authorHinton, W
dc.contributor.authorMayor, N
dc.contributor.authorKar, D
dc.contributor.authorWilliams, J
dc.contributor.authorVictor, W
dc.contributor.authorAkbari, A
dc.contributor.authorBradley, DT
dc.contributor.authorMurphy, S
dc.contributor.authorO’Reilly, D
dc.contributor.authorOwen, RK
dc.contributor.authorChuter, A
dc.contributor.authorBeggs, J
dc.contributor.authorHowsam, G
dc.contributor.authorSheikh, A
dc.contributor.authorHobbs, FDR
dc.contributor.authorde Lusignan, S
dc.date.accessioned2024-03-07T15:28:51Z
dc.date.available2024-03-07T15:28:51Z
dc.date.issued2023-01-19
dc.identifier.issn1560-7917
dc.identifier.issn1560-7917
dc.identifier.urihttps://pearl.plymouth.ac.uk/handle/10026.1/22137
dc.description.abstract

<jats:sec> <jats:title>Background</jats:title> <jats:p>Post-authorisation vaccine safety surveillance is well established for reporting common adverse events of interest (AEIs) following influenza vaccines, but not for COVID-19 vaccines.</jats:p> </jats:sec> <jats:sec> <jats:title>Aim</jats:title> <jats:p>To estimate the incidence of AEIs presenting to primary care following COVID-19 vaccination in England, and report safety profile differences between vaccine brands.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We used a self-controlled case series design to estimate relative incidence (RI) of AEIs reported to the national sentinel network, the Oxford-Royal College of General Practitioners Clinical Informatics Digital Hub. We compared AEIs (overall and by clinical category) 7 days pre- and post-vaccination to background levels between 1 October 2020 and 12 September 2021.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Within 7,952,861 records, 781,200 individuals (9.82%) presented to general practice with 1,482,273 AEIs, 4.85% within 7 days post-vaccination. Overall, medically attended AEIs decreased post-vaccination against background levels. There was a 3–7% decrease in incidence within 7 days after both doses of Comirnaty (RI: 0.93; 95% CI: 0.91–0.94 and RI: 0.96; 95% CI: 0.94–0.98, respectively) and Vaxzevria (RI: 0.97; 95% CI: 0.95–0.98). A 20% increase was observed after one dose of Spikevax (RI: 1.20; 95% CI: 1.00–1.44). Fewer AEIs were reported as age increased. Types of AEIs, e.g. increased neurological and psychiatric conditions, varied between brands following two doses of Comirnaty (RI: 1.41; 95% CI: 1.28–1.56) and Vaxzevria (RI: 1.07; 95% CI: 0.97–1.78).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>COVID-19 vaccines are associated with a small decrease in medically attended AEI incidence. Sentinel networks could routinely report common AEI rates, contributing to reporting vaccine safety.</jats:p> </jats:sec>

dc.format.extent20-32
dc.format.mediumPrint
dc.languageen
dc.publisherEuropean Centre for Disease Control and Prevention (ECDC)
dc.subjectCOVID-19
dc.subjectCOVID-19 Vaccines
dc.subjectDrug-Related Side Effects and Adverse Reactions
dc.subjectMedical record systems, computerised
dc.subjectPrimary care
dc.subjectSNOMED CT
dc.subjectSentinel surveillance
dc.subjectVaccination
dc.subjectHumans
dc.subjectBNT162 Vaccine
dc.subjectChAdOx1 nCoV-19
dc.subjectCOVID-19
dc.subjectCOVID-19 Vaccines
dc.subjectEngland
dc.subjectInfluenza Vaccines
dc.subjectVaccination
dc.titleAdverse events following first and second dose COVID-19 vaccination in England, October 2020 to September 2021: a national vaccine surveillance platform self-controlled case series study
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36695484
plymouth.issue3
plymouth.volume28
plymouth.publisher-urlhttp://dx.doi.org/10.2807/1560-7917.es.2023.28.3.2200195
plymouth.publication-statusPublished
plymouth.journalEurosurveillance
dc.identifier.doi10.2807/1560-7917.es.2023.28.3.2200195
plymouth.organisational-group|Plymouth
plymouth.organisational-group|Plymouth|Faculty of Health
plymouth.organisational-group|Plymouth|Users by role
plymouth.organisational-group|Plymouth|Users by role|Academics
plymouth.organisational-group|Plymouth|Faculty of Health|Peninsula Medical School
dc.publisher.placeSweden
dc.date.updated2024-03-07T15:28:50Z
dc.identifier.eissn1560-7917
dc.rights.embargoperiodforever
rioxxterms.versionofrecord10.2807/1560-7917.es.2023.28.3.2200195


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV